Phathom Pharmaceuticals Net Income
| PHAT Stock | USD 12.58 0.17 1.37% |
As of the 7th of February, Phathom Pharmaceuticals holds the insignificant Risk Adjusted Performance, coefficient of variation of (6,266), and Variance of 14.44. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Phathom Pharmaceuticals, as well as the relationship between them.
Phathom Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.5193 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -300.9 M | -285.8 M | |
| Net Loss | -178 M | -186.8 M | |
| Net Loss | -300.9 M | -285.8 M | |
| Net Loss | (6.09) | (6.39) | |
| Net Income Per E B T | 0.74 | 0.66 |
Phathom | Net Income | Build AI portfolio with Phathom Stock |
The evolution of Net Income for Phathom Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Phathom Pharmaceuticals compares to historical norms and industry peers.
Latest Phathom Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Phathom Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Phathom Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Phathom Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Phathom Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Phathom Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (334.33 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Phathom Net Income Regression Statistics
| Arithmetic Mean | (106,745,302) | |
| Coefficient Of Variation | (117.43) | |
| Mean Deviation | 111,660,672 | |
| Median | (1,288,000) | |
| Standard Deviation | 125,353,191 | |
| Sample Variance | 15713.4T | |
| Range | 333M | |
| R-Value | (0.89) | |
| Mean Square Error | 3375.2T | |
| R-Squared | 0.80 | |
| Slope | (22,183,855) | |
| Total Sum of Squares | 251414.8T |
Phathom Net Income History
Other Fundumenentals of Phathom Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Phathom Pharmaceuticals Net Income component correlations
Phathom Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Phathom Pharmaceuticals is extremely important. It helps to project a fair market value of Phathom Stock properly, considering its historical fundamentals such as Net Income. Since Phathom Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Phathom Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Phathom Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Pharmaceuticals market expansion? Will Phathom introduce new products? Factors like these will boost the valuation of Phathom Pharmaceuticals. Anticipated expansion of Phathom directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Phathom Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.53) | Revenue Per Share | Quarterly Revenue Growth 2.027 | Return On Assets | Return On Equity |
The market value of Phathom Pharmaceuticals is measured differently than its book value, which is the value of Phathom that is recorded on the company's balance sheet. Investors also form their own opinion of Phathom Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phathom Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Phathom Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phathom Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Phathom Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Phathom Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Phathom Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Phathom Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Phathom Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Phathom Pharmaceuticals.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Phathom Pharmaceuticals on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Phathom Pharmaceuticals or generate 0.0% return on investment in Phathom Pharmaceuticals over 90 days. Phathom Pharmaceuticals is related to or competes with Nurix Therapeutics, Kodiak Sciences, Xencor, UroGen Pharma, Bicara Therapeutics, Oculis Holding, and BridgeBio Oncology. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing tre... More
Phathom Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Phathom Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Phathom Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 24.16 | |||
| Value At Risk | (5.30) | |||
| Potential Upside | 5.99 |
Phathom Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Phathom Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Phathom Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Phathom Pharmaceuticals historical prices to predict the future Phathom Pharmaceuticals' volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | (0.20) |
Phathom Pharmaceuticals February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 2.84 | |||
| Coefficient Of Variation | (6,266) | |||
| Standard Deviation | 3.8 | |||
| Variance | 14.44 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 24.16 | |||
| Value At Risk | (5.30) | |||
| Potential Upside | 5.99 | |||
| Skewness | (0.22) | |||
| Kurtosis | 2.11 |
Phathom Pharmaceuticals Backtested Returns
Phathom Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of -0.0173, which implies the firm had a -0.0173 % return per unit of risk over the last 3 months. Phathom Pharmaceuticals exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Phathom Pharmaceuticals' Variance of 14.44, insignificant risk adjusted performance, and Coefficient Of Variation of (6,266) to confirm the risk estimate we provide. The company holds a Beta of 0.36, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Phathom Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Phathom Pharmaceuticals is expected to be smaller as well. At this point, Phathom Pharmaceuticals has a negative expected return of -0.0676%. Please make sure to check Phathom Pharmaceuticals' jensen alpha, as well as the relationship between the skewness and day median price , to decide if Phathom Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.56 |
Good reverse predictability
Phathom Pharmaceuticals has good reverse predictability. Overlapping area represents the amount of predictability between Phathom Pharmaceuticals time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Phathom Pharmaceuticals price movement. The serial correlation of -0.56 indicates that roughly 56.0% of current Phathom Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.56 | |
| Spearman Rank Test | -0.31 | |
| Residual Average | 0.0 | |
| Price Variance | 2.33 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Phathom Pharmaceuticals reported net income of (334.33 Million). This is 197.96% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 158.55% higher than that of the company.
Phathom Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phathom Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phathom Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phathom Pharmaceuticals by comparing valuation metrics of similar companies.Phathom Pharmaceuticals is currently under evaluation in net income category among its peers.
Phathom Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Phathom Pharmaceuticals from analyzing Phathom Pharmaceuticals' financial statements. These drivers represent accounts that assess Phathom Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Phathom Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 727.8M | 438.9M | 468.3M | 513.0M | 589.9M | 665.2M | |
| Enterprise Value | 865.4M | 635.9M | 380.6M | 225.9M | 259.8M | 246.8M |
Phathom Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Phathom Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Phathom Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Phathom Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Phathom Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Phathom Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Phathom Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 1.1 M | Avidity Partners Management Lp | 2025-06-30 | 1.1 M | Gw&k Investment Management, Llc | 2025-06-30 | 1 M | Propel Bio Management Llc | 2025-06-30 | 922.9 K | State Street Corp | 2025-06-30 | 849.4 K | Catalio Capital Management, Lp | 2025-06-30 | 672.3 K | Moore Capital Management, Lp | 2025-06-30 | 600 K | Simplify Asset Management Inc. | 2025-06-30 | 521.9 K | Citigroup Inc | 2025-06-30 | 517.2 K | Medicxi Ventures Management (jersey) Ltd | 2025-06-30 | 7.5 M | Amvescap Plc. | 2025-06-30 | 4.1 M |
Phathom Fundamentals
| Return On Equity | -34.89 | ||||
| Return On Asset | -0.43 | ||||
| Profit Margin | (1.87) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 1.11 B | ||||
| Shares Outstanding | 78.01 M | ||||
| Shares Owned By Insiders | 4.69 % | ||||
| Shares Owned By Institutions | 77.30 % | ||||
| Number Of Shares Shorted | 10.52 M | ||||
| Price To Book | 25.37 X | ||||
| Price To Sales | 6.58 X | ||||
| Revenue | 55.25 M | ||||
| Gross Profit | 128.42 M | ||||
| EBITDA | (261.52 M) | ||||
| Net Income | (334.33 M) | ||||
| Cash And Equivalents | 207.39 M | ||||
| Cash Per Share | 5.39 X | ||||
| Total Debt | 554.95 M | ||||
| Debt To Equity | 2.43 % | ||||
| Current Ratio | 9.93 X | ||||
| Book Value Per Share | (5.95) X | ||||
| Cash Flow From Operations | (266.77 M) | ||||
| Short Ratio | 8.04 X | ||||
| Earnings Per Share | (3.53) X | ||||
| Target Price | 22.9 | ||||
| Number Of Employees | 427 | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 968.15 M | ||||
| Total Asset | 378.32 M | ||||
| Retained Earnings | (1.26 B) | ||||
| Working Capital | 274.41 M | ||||
| Net Asset | 378.32 M |
About Phathom Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phathom Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phathom Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phathom Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.